Medical Technology

@xconomy.com 3 years ago

Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

@xconomy.com 3 years ago

Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue

@xconomy.com 3 years ago

Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally

@xconomy.com 3 years ago

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019

@xconomy.com 4 years ago

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

@xconomy.com 4 years ago

Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 4 years ago

Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

@xconomy.com 5 years ago

Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues

@xconomy.com 5 years ago

ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More

@xconomy.com 5 years ago

Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More